Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 6/20 | 0.39 |
| ▸ | FEN1 | P39748 | 6/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
| ▸ | DNASE1 | P24855 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930728 | 0.93 | ERCC1 (0.37) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23611743 | 0.93 | ERCC1 (0.37) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23623421 | 0.92 | MYC (0.38) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23623315 | 0.91 | ERCC1 (0.38) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23623340 | 0.87 | ERCC1 (0.35) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23623298 | 0.81 | HPGD (0.40) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23623266 | 0.77 | HPGD (0.40) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23623261 | 0.76 | HPGD (0.41) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL23611763 | 0.74 | HPGD (0.41) | ERCC1FEN1ERCC4HPGDALDH1A1 | |
| SCHEMBL29930610 | 0.74 | HPGD (0.41) | ERCC1FEN1ERCC4HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091590-A1 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | BERG LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| WO-2021138540-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | BERG LLC (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | ERCC1 1473/4885FEN1 3856/4885ERCC4 697/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | ERCC1 1473/4885FEN1 3856/4885ERCC4 697/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | ERCC1 1473/4885FEN1 3856/4885ERCC4 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.